Zongkuai Yang
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Structure-based design of non-hypertrophic apelin receptor modulator.
Journal: Cell
Published: August 06, 2026
WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy.
Journal: Circulation
Published: April 17, 2026
TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy.
Journal: Circulation research
Published: February 25, 2026
iPSC-derived cardiomyocytes and engineered heart tissues reveal suppressed JAK2/STAT3 signaling in LMNA-related emery-dreifuss muscular dystrophy.
Journal: Redox biology
Published: March 06, 2025
Generation of a human induced pluripotent stem cell line from a hypertrophic cardiomyopathy patient carrying MYH6/c.611G>A mutation.
Journal: Stem cell research
Published: March 28, 2024
Structure-based design of non-hypertrophic apelin receptor modulator.
Journal: Cell
Published: June 01, 2023
Patient-specific iPSC-derived cardiomyocytes reveal aberrant activation of Wnt/β-catenin signaling in SCN5A-related Brugada syndrome.
Journal: Stem cell research & therapy
Published: January 12, 2023
Hyperactivation of platelet-derived growth factor signalling contributes to arrhythmogenesis in Brugada syndrome.
Journal: Clinical and translational medicine
Published: October 29, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026